Strategic partnerships Bedrocan collaborates with the Dutch Office of Medicinal Cannabis (OMC) to supply medicinal cannabis as API to pharmaceutical manufacturers and international governments under special access conditions, presenting a channel for co-development, contract manufacturing, and regulatory-aligned opportunities.

Expanded product line Recent launch of Bedromed a line of standardised cannabinoid-based formulations opens doors for white-labeling, private-label partnerships, and rapid entry into new CBPM product categories for pharma clients seeking standardized cannabis components.

Clinical research Active patient-focused research and published findings position Bedrocan as a credible API supplier for clinical trials, enabling partnerships with biotech or pharma developers seeking reliable cannabis-based investigational products and study-ready materials.

Global access Bedrocan’s supply to multiple international governments under special access frameworks indicates a ready-to-scale export capability for API-grade cannabis, suggesting opportunities with multinational pharma manufacturers and government procurement programs.

Technology & compliance A tech stack including analytics and monitoring tools plus established quality standards signals strong data-driven operations and regulatory compliance, which can reassure potential clients and streamline onboarding for new manufacturing collaborations.